首页> 美国卫生研究院文献>Reproductive Biology and Endocrinology : RBE >Tranylcypromine a lysine-specific demethylase 1 (LSD1) inhibitor suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis
【2h】

Tranylcypromine a lysine-specific demethylase 1 (LSD1) inhibitor suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis

机译:Tranylcypromine一种赖氨酸特异性脱甲基酶1(LSD1)抑制剂可抑制小鼠子宫内膜异位症的病变生长并改善全身痛觉过敏

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundGrowing evidence indicates that endometriosis is an epigenetic disease. Encouragingly, histone deacetylases (HDACs) and DNA methyltransferases have been shown to be promising targets by numerous in vitro studies. However, only a few studies have shown promising effects of HDAC inhibition in preclinical studies in endometriosis. While lysine-specific demethylase 1 (LSD1) is recently found to be aberrantly expressed in endometriosis, and that the treatment of endometriotic stromal cells with tranylcypromine (TC), an LSD1 inhibitor, significantly reduced cellular proliferation, cell cycle progression, and invasiveness, the in vivo effect of TC treatment is currently lacking. This study sought to evaluate the effect of TC in a mouse model of endometriosis.
机译:背景越来越多的证据表明子宫内膜异位是一种表观遗传疾病。令人鼓舞的是,许多体外研究表明,组蛋白脱乙酰基酶(HDAC)和DNA甲基转移酶是有希望的靶标。但是,只有很少的研究表明在子宫内膜异位症的临床前研究中,HDAC抑制作用的前景看好。虽然最近发现赖氨酸特异性脱甲基酶1(LSD1)在子宫内膜异位症中异常表达,并且使用LSD1抑制剂tranylcypromine(TC)治疗子宫内膜异位基质细胞显着降低了细胞增殖,细胞周期进程和侵袭性,目前尚缺乏TC治疗的体内作用。这项研究试图评估TC在子宫内膜异位症小鼠模型中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号